Share on StockTwits

Questcor Pharmaceuticals (NASDAQ:QCOR) Insider Michael H. Mulroy sold 10,000 shares of Questcor Pharmaceuticals stock in a transaction dated Tuesday, June 10th. The shares were sold at an average price of $88.57, for a total value of $885,700.00. Following the completion of the transaction, the insider now directly owns 77,063 shares of the company’s stock, valued at approximately $6,825,470. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

QCOR has been the subject of a number of recent research reports. Analysts at Mizuho downgraded shares of Questcor Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note on Monday, May 19th. They now have a $92.00 price target on the stock. Separately, analysts at Piper Jaffray downgraded shares of Questcor Pharmaceuticals from an “overweight” rating to a “neutral” rating in a research note on Monday, May 12th. They now have a $98.00 price target on the stock, up previously from $96.00. Finally, analysts at Oppenheimer reiterated an “outperform” rating on shares of Questcor Pharmaceuticals in a research note on Monday, April 21st. They now have a $86.00 price target on the stock, down previously from $99.00. Six research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Questcor Pharmaceuticals presently has an average rating of “Hold” and an average target price of $84.20.

Questcor Pharmaceuticals (NASDAQ:QCOR) traded down 2.40% on Thursday, hitting $88.81. The stock had a trading volume of 1,188,705 shares. Questcor Pharmaceuticals has a 52 week low of $42.01 and a 52 week high of $94.20. The stock’s 50-day moving average is $87.33 and its 200-day moving average is $69.79. The company has a market cap of $5.252 billion and a price-to-earnings ratio of 17.18.

Questcor Pharmaceuticals (NASDAQ:QCOR) last issued its quarterly earnings data on Monday, April 28th. The company reported $1.40 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.61 by $0.21. The company had revenue of $227.10 million for the quarter, compared to the consensus estimate of $239.81 million. During the same quarter in the previous year, the company posted $0.76 earnings per share. The company’s revenue for the quarter was up 68.1% on a year-over-year basis. Analysts expect that Questcor Pharmaceuticals will post $6.89 EPS for the current fiscal year.

Questcor Pharmaceuticals, Inc (NASDAQ:QCOR) is a biopharmaceutical company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.